218 related articles for article (PubMed ID: 24236193)
1. Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.
Li Z; Zou X; Xie L; Dong H; Chen Y; Liu Q; Wu X; Zhou D; Tan D; Zhang H
PLoS One; 2013; 8(11):e80665. PubMed ID: 24236193
[TBL] [Abstract][Full Text] [Related]
2. Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.
Li Z; Zou X; Xie L; Chen H; Chen Y; Yeung SC; Zhang H
Int J Cancer; 2015 Apr; 136(7):1636-45. PubMed ID: 25159681
[TBL] [Abstract][Full Text] [Related]
3. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
van Dekken H; Tilanus HW; Hop WC; Dinjens WN; Wink JC; Vissers KJ; van Marion R
Cancer Genet Cytogenet; 2009 Feb; 189(1):37-42. PubMed ID: 19167610
[TBL] [Abstract][Full Text] [Related]
4. The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma.
Dong H; Guo H; Xie L; Wang G; Zhong X; Khoury T; Tan D; Zhang H
PLoS One; 2013; 8(5):e62986. PubMed ID: 23671646
[TBL] [Abstract][Full Text] [Related]
5. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of PAK1 Is Associated with DNA Damage and Is of Prognostic Importance in Primary Esophageal Small Cell Carcinoma.
Gan J; Zhang Y; Ke X; Tan C; Ren H; Dong H; Jiang J; Chen S; Zhuang Y; Zhang H
Int J Mol Sci; 2015 May; 16(6):12035-50. PubMed ID: 26023713
[TBL] [Abstract][Full Text] [Related]
8. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
Treacy AD; Karamchandani JR; Streutker CJ; Grin A
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction.
Bornschein J; Wernisch L; Secrier M; Miremadi A; Perner J; MacRae S; O'Donovan M; Newton R; Menon S; Bower L; Eldridge MD; Devonshire G; Cheah C; Turkington R; Hardwick RH; Selgrad M; Venerito M; Malfertheiner P; ; Fitzgerald RC
Int J Cancer; 2019 Dec; 145(12):3389-3401. PubMed ID: 31050820
[TBL] [Abstract][Full Text] [Related]
11. ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
El Jabbour T; Misyura M; Cowzer D; Zimmermann M; Rimkunas V; Marra A; Derakhshan F; Selenica P; Parilla M; Setton JS; Ceyhan-Birsoy O; Kemel Y; Catchings A; Ranganathan M; Ku GY; Janjigian YY; Zinda M; Koehler M; Stadler Z; Shia J; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2022 May; 114(5):761-770. PubMed ID: 35078243
[TBL] [Abstract][Full Text] [Related]
12. CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy.
Fisher OM; Levert-Mignon AJ; Lehane CW; Botelho NK; Maag JL; Thomas ML; Edwards M; Lord SJ; Bobryshev YV; Whiteman DC; Lord RV
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):746-754. PubMed ID: 27577713
[TBL] [Abstract][Full Text] [Related]
13. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.
van Duin M; van Marion R; Vissers KJ; Hop WC; Dinjens WN; Tilanus HW; Siersema PD; van Dekken H
Cytogenet Genome Res; 2007; 118(2-4):130-7. PubMed ID: 18000363
[TBL] [Abstract][Full Text] [Related]
14. Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas.
Bain GH; Collie-Duguid E; Murray GI; Gilbert FJ; Denison A; McKiddie F; Ahearn T; Fleming I; Leeds J; Phull P; Park K; Nanthakumaran S; Matula KM; Grabsch HI; Tan P; Welch A; Schweiger L; Dahle-Smith A; Urquhart G; Finegan M; Petty RD
Br J Cancer; 2014 Mar; 110(6):1525-34. PubMed ID: 24569475
[TBL] [Abstract][Full Text] [Related]
15. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
16. Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma.
Dong H; Xie L; Tang C; Chen S; Liu Q; Zhang Q; Zheng W; Zheng Z; Zhang H
Clin Transl Oncol; 2014 Sep; 16(9):783-91. PubMed ID: 24356933
[TBL] [Abstract][Full Text] [Related]
17. [Adenocarcinoma of the gastro-esophageal junction].
Huang Q; Fan XS; Shi J; Zhang YF; Feng AN; Wu HY; Sun Q; Zhou Q; Yu HP; Meng FQ; Wang JM
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):793-5. PubMed ID: 23324225
[No Abstract] [Full Text] [Related]
18. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Resetkova E; Wang H; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Hamilton SR; Albarracin CT
Clin Cancer Res; 2006 Aug; 12(15):4598-604. PubMed ID: 16899607
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
20. Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
Ann Surg Oncol; 2007 Feb; 14(2):306-16. PubMed ID: 17091329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
